secwatch.observer — SEC 8-K summary
======================================

Issuer:     Milestone Pharmaceuticals Inc. (MIST)
CIK:        0001408443
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001104659-23-116646
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Milestone Pharma reports Q3 2023 results; NDA submitted for etripamil in PSVT
-----------------------------------------------------------------------------

- Cash $75.7M as of Sep 30, 2023; expected to fund operations into mid-2025.
- Q3 operating loss $15.4M vs $15.0M prior year; R&D expense down to $6.7M.
- NDA for etripamil (CARDAMYST) in PSVT submitted to FDA; acceptance decision by end of 2023.
- Positive Phase 2 ReVeRA data for etripamil in AFib-RVR presented at AHA; Phase 3 program to start mid-2024.
- Commercial expense rose to $4.4M in Q3 from $2.7M prior year, building pre-launch capabilities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1408443/000110465923116646/0001104659-23-116646-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1408443/000110465923116646/tm2330492d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-116646

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer